Abbott Laboratories vs Medtronic ABT vs MDT
Abbott Laboratories and Medtronic on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
ABTMDT
What differs most
- One-year price return: Medtronic +1.2%, Abbott Laboratories −17.3%.
- Trailing P/E: Abbott Laboratories 39.0×, Medtronic 23.3×.
- EV / EBITDA: Abbott Laboratories 21.7×, Medtronic 14.4×.
- Market value: Abbott Laboratories $181.48B, Medtronic $121.25B.
Price return
2025-10-26 → 2026-10-26
ABT−17.3%
MDT+1.2%
Profile
latestSector
Healthcare
Healthcare
Industry
Medical - Devices
Medical - Devices
Market value
$181.48B
$121.25B
Enterprise value
$208.99B
$147.71B
Employees
115,000
95,000
Revenue per employee (TTM)
$419K
$395K
Our models
nightlythe valuation on each stock's pagePrice vs model
19% overvalued vs model
32% overvalued vs model
Model range
$56.37–209
$40.21–215
Models in the headline
1
1
FCF growth priced in, at a 10% return
13.8%
14.1%
Every model, its assumptions and its range: ABT valuation · MDT valuation. The growth priced in, at any return: ABT reverse DCF · MDT reverse DCF.
Trading
close 2026-10-26Last close
$104.88
$94.79
52-week high
$130.59
$105.35
52-week low
$82.56
$73.75
Price vs 52-week high
−19.7%
−10.0%
Price vs 52-week low
+27.0%
+28.5%
Average daily volume / shares
0.6%
1.1%
Beta
0.58
0.57
Returns
to 2026-10-261 month
+3.5%
+6.9%
3 months
+1.8%
+13.9%
6 months
+15.1%
+13.8%
Year to date
−16.3%
−1.3%
1 year
−17.3%
+1.2%
1 year, dividends added
−15.3%
+4.2%
2 years
−8.2%
+4.6%
Valuation
ABT price × TTM to Sep 2026 · MDT price × TTM to Jul 2026P/E (TTM)
39.0×
23.3×
P/E on consensus EPS (next FY)
19.0×
15.9×
Price / sales
3.8×
3.2×
EV / sales
4.3×
3.9×
EV / EBITDA
21.7×
14.4×
Price / book
3.6×
2.4×
Price / free cash flow (FY)
24.5×
22.3×
Free-cash-flow yield (FY)
4.1%
4.5%
Growth
ABT TTM and FY2025 · MDT TTM and FY2026Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+13.0%
+7.4%
Revenue, 3-year CAGR
0.5%
5.2%
Revenue, 5-year CAGR
5.1%
3.8%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+48.4%
+60.2%
EPS, 3-year CAGR
−1.6%
9.8%
Free cash flow, 3-year CAGR
−1.8%
5.8%
Diluted shares, 3-year change
−1.0%
−3.4%
Profitability
ABT TTM to Sep 2026 · MDT TTM to Jul 2026Gross margin (FY)†
55.5%
0.0%
Operating margin
15.2%
18.1%
EBITDA margin
20.0%
27.4%
Net margin
9.7%
13.9%
Free-cash-flow margin (FY)
16.7%
14.9%
Return on equity
9.2%
10.4%
Return on assets
4.3%
5.6%
Asset turnover
0.44
0.40
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
ABT MRQ Jun 2026 · MDT MRQ Jul 2026Cash
$5.10B
$1.69B
Total debt
$32.61B
$28.15B
Net debt
$27.50B
$26.46B
Debt / equity
0.6×
0.6×
Net debt / EBITDA (TTM)
2.9×
2.6×
Interest coverage (FY)
23.6×
9.0×
Current ratio (FY)
1.58
0.00
Dividends
trailing 12 monthsDividend yield
2.4%
3.0%
Dividends per share
$2.52
$2.86
Payout ratio (of TTM EPS)
93.6%
70.4%
Dividend per share, 5-year CAGR
7.0%
3.4%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
9
9
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$46.9M
$5.9M
Analyst upgrades
2
1
Analyst downgrades
0
0
Statements
ABT income TTM to Sep 2026 · cash flow FY2025 · MDT income TTM to Jul 2026 · cash flow FY2026Revenue
$48.23B
$37.54B
EBITDA
$9.63B
$10.27B
Operating income
$7.35B
$6.79B
Net income
$4.70B
$5.23B
EPS (diluted)
$2.69
$4.06
Operating cash flow
$9.57B
$7.33B
Capital expenditure
−$2.17B
−$1.90B
Free cash flow
$7.39B
$5.43B
Dividends paid
$4.12B
$3.64B
Keep comparing
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.